Cited by 333Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Open access

Curtis, Craig, Gamez, Jose E., Singh, Upinder, Sadowsky, Carl H., Villena, Teresa, Sabbagh, Marwan N., Beach, Thomas G., Duara, Ranjan, Fleisher, Adam S., Frey, Kirk A., Walker, Zuzana, Hunjan, Arvinder, Holmes, Clive, Escovar, Yavir M., Vera, Carla X., Agronin, Marc E., Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D., Sherwin, Paul F., Grachev, Igor D., Farrar, Gillian, Smith, Adrian P. L., Buckley, Christopher J., McLain, Richard, Salloway, Stephen·2015·JAMA Neurology

DOI 10.1001/jamaneurol.2014.4144

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist in the clinical assessment of suspected Alzheimer disease. OBJECTIVE: To determine the sensitivity and specificity of positron emission tomography imaging with flutemetamol injection labeled with radioactive fluorine 18 to detect β-amyloid in the brain using neuropathologically determined neuritic plaque levels as the standard of truth. DESIGN, SETTING, AND PARTICIPANTS: Open-label multicenter imaging study that took place at dementia clinics, memory centers, and hospice centers in the United States and England from June 22, 2010, to November 23, 2011. Participants included terminally ill patients who were 55 years or older with a life expectancy of less than 1 year. INTERVENTIONS: Flutemetamol injection labeled with radioactive fluorine 18 (Vizamyl; GE Healthcare) administration followed by positron emission tomography imaging and subsequent brain donation. MAIN OUTCOMES AND MEASURES: Sensitivity and specificity of flutemetamol injection labeled with radioactive fluorine 18 positron emission tomography imaging for brain β-amyloid. Images were reviewed without and with computed tomography scans and classified as positive or negative for β-amyloid by 5 readers who were blind to patient information. In patients who died, neuropathologically determined neuritic plaque levels were used to confirm scan interpretations and determine sensitivity and specificity. RESULTS: Of 176 patients with evaluable images, 68 patients (38%) died during the study, were autopsied, and had neuritic plaque levels determined; 25 brains (37%) were β-amyloid negative; and 43 brains (63%) were β-amyloid positive. Imaging was performed a mean of 3.5 months (range, 0 to 13 months) before death. Sensitivity without computed tomography was 81% to 93% (median, 88%). Median specificity was 88%, with 4 of 5 of the readers having specificity greater than 80%. When scans were interpreted with computed tomography images, sensitivity and specificity improved for most readers but the differences were not significant. The area under the receiver operating curve was 0.90. There were no clinically meaningful findings in safety parameters. CONCLUSIONS AND RELEVANCE: This study showed that flutemetamol injection labeled with radioactive fluorine 18 was safe and had high sensitivity and specificity in an end-of-life population. In vivo detection of brain β-amyloid plaque density may increase diagnostic accuracy in cognitively impaired patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2014.4144

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citation
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Statistical Methods in Diagnostic Medicine
Zhou, X., Sun, J., Pennello, G. A., Obuchowski, N. A., & McClish, D. K. (2011) · Wiley series in probability and statistics · doi:10.1002/9780470906514 · Cited by 1,785
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Statistical Methods in Diagnostic Medicine
Zhou, X., Obuchowski, N. A., & McClish, D. K. (2002) · Wiley series in probability and statistics · doi:10.1002/9780470317082 · Cited by 1,166
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“39) [0-30] 8.”
Self-citation
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933

Show all 30 references

Sorted by citations

Alzheimer’s Disease
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citation
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citation
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Alzheimer's disease
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604
Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Fleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448
Self-citation
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 447
Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation
Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408
Neuropathology of Alzheimer's Disease
Trejo‐Lopez, J. A., Yachnis, A. T., & Prokop, S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01146-y · Cited by 419
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
Self-citation
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean‐Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Cainap, C. I., & Chiş, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 386
Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
La Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease
Portelius, E., Zetterberg, H., Skillbäck, T., Törnqvist, U., Andreasson, U., Trojanowski, J. Q., Weiner, M. W., Shaw, L. M., & Mattsson, N. (2015) · Brain · doi:10.1093/brain/awv267 · Cited by 279
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Schindler, S. E., Galasko, D. R., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez‐Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh‐Momoh, C. T., Weiss, J. O., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00977-5 · Cited by 348
Self-citation
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 346
Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric Aβ and Tau Species
Chen, X., & Mobley, W. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00659 · Cited by 302
Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection
Teipel, S. J., Drzezga, A. E., Grothe, M. J., Barthel, H., Chételat, G., Schuff, N. W., Skudlarski, P., Cavedo, E., Frisoni, G. B., Hoffmann, W. U., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00093-9 · Cited by 285
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
Self-citation
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
Chapleau, M., Iaccarino, L., Soleimani‐Meigooni, D. N., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263195 · Cited by 276
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
Pontecorvo, M. J., Devous, M. D., Kennedy, I., Navitsky, M., Lu, M., Galante, N., Salloway, S., Doraiswamy, P. M., Southekal, S., Arora, A. K., et al. (2019) · Brain · doi:10.1093/brain/awz090 · Cited by 249
Self-citation
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Tau PET imaging with 18 F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
Mueller, A., Bullich, S., Barret, O., Madonia, J., Berndt, M., Papin, C., Perrotin, A., Koglin, N., Kroth, H., Pfeifer, A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236224 · Cited by 195
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
Amadoru, S., Doré, V., McLean, C. A., Hinton, F., Shepherd, C. E., Halliday, G. M., Leyton, C. E., Yates, P. A., Hodges, J. R., Masters, C. L., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00587-5 · Cited by 181
[ 18 F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid‐β pathology
Thal, D. R., Beach, T. G., Zanette, M., Heurling, K., Chakrabarty, A., Ismail, A., Smith, A. P. L., & Buckley, C. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.018 · Cited by 159
Self-citation
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—A systematic review
Rice, L., & Bisdas, S. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.07.014 · Cited by 156
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 163
Self-citation
Molecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomović, M. D., Counts, S., Perez, S. E., Malek‐Ahmadi, M. H., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 134
Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment
Iaccarino, L., Joie, R. L., Lesman‐Segev, O. H., Lee, E. Y., Hanna, L., Allen, I. E., Hillner, B. E., Siegel, B. A., Whitmer, R. A., Carrillo, M. C., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3962 · Cited by 125
Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium
Collij, L. E., Bollack, A., Joie, R. L., Shekari, M., Bullich, S., Roé-Vellvé, N., Koglin, N., Jovalekic, A., García, D. V., Drzezga, A. E., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14336 · Cited by 130
Self-citation
Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study
J-ADNI Study Group, Yamane, T., Ishii, K., Sakata, M., Ikari, Y., Nishio, T., Ishii, K., Kato, T., Ito, K., & Senda, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3591-2 · Cited by 121
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Is amyloid-β harmful to the brain? Insights from human imaging studies
Jagust, W. (2016) · Brain · doi:10.1093/brain/awv326 · Cited by 110
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 112
PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape
Uzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 107
Comparison of 18F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL® approaches: Validation against histopathology
Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
Ikonomović, M. D., Buckley, C. J., Heurling, K., Sherwin, P. F., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J. W., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0399-z · Cited by 102
Self-citation
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Self-citation
Differential diagnosis between patients with probable Alzheimer’s disease, Parkinson’s disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features
Garn, H., Coronel, C., Waser, M., Caravias, G., & Ransmayr, G. N. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1699-6 · Cited by 113
Pitfalls and Limitations of PET/CT in Brain Imaging
Salmon, É., Bernard, C., & Hustinx, R. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.03.008 · Cited by 90
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
Salloway, S., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.06.001 · Cited by 87
Self-citation
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 87
Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice
Ni, R., Chen, Z., Deán‐Ben, X. L., Voigt, F. F., Kirschenbaum, D. S., Shi, G., Villois, A., Zhou, Q., Crimi, A., Arosio, P., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00906-1 · Cited by 84
Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer’s Disease
Macdonald, I. R., Maxwell, S. P., Reid, G. A., Cash, M. K., DeBay, D. R., & Darvesh, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170164 · Cited by 85
Alzheimer Disease
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
Self-citation
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 87
Diagnostic Accuracy of Amyloid versus FDG PET in Patients with Cognitive Impairment and Autopsy
Lesman‐Segev, O. H., Joie, R. L., Iaccarino, L., Lobach, I. V., Rosen, H. J., Seo, S. W., Janabi, M., Baker, S. L., Edwards, L., Pham, J. Q., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25968 · Cited by 82
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 87
Self-citation
The EMIF-AD PreclinAD study: study design and baseline cohort overview
Konijnenberg, E., Carter, S. F., ten Kate, M., den Braber, A., Tomassen, J., Amadi, C., Wesselman, L. M. P., Nguyen, H., van de Kreeke, J. A., Yaqub, M. M., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0406-7 · Cited by 77
Structural mechanism for specific binding of chemical compounds to amyloid fibrils
Tao, Y., Xia, W., Zhao, Q., Xiang, H., Han, C., Zhang, S., Gu, W., Tang, W., Li, Y., Tan, L., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01370-x · Cited by 74
Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol β-amyloid PET brain images
Buckley, C. J., Sherwin, P. F., Smith, A. P. L., Wolber, J., Weick, S. M., & Brooks, D. J. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000633 · Cited by 70
Self-citation
Applications of nanobodies in brain diseases
Zheng, F., Pang, Y., Li, L., Pang, Y., Zhang, J., Wang, X., & Raes, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978513 · Cited by 69
Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects
Mountz, J. M., Laymon, C. M., Cohen, A. D., Zhang, Z., Price, J. C., Boudhar, S., McDade, E., Aizenstein, H. J., Klunk, W. E., & Mathis, C. A. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.10.007 · Cited by 73
Diffusion MRI biomarkers of white matter microstructure vary nonmonotonically with increasing cerebral amyloid deposition
Dong, J. W., Jelescu, I. O., Ades-Aron, B., Novikov, D. S., Friedman, K., Babb, J. S., Osorio, R. S., Galvin, J. E., Shepherd, T. M., & Fieremans, E. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.009 · Cited by 70
Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging
(ADNI), F. T. A. D. N. I., Yan, Q., Nho, K., Del-Aguila, J. L., Wang, X., Risacher, S. L., Fan, K.-H., Snitz, B. E., Aizenstein, H. J., Mathis, C. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-018-0246-7 · Cited by 73
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent
Collij, L. E., Salvadó, G., Shekari, M., Alves, I. L., Reimand, J., Wink, A. M., Zwan, M. D., Niñerola‐Baizán, A., Perissinotti, A., Scheltens, P., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05174-2 · Cited by 71
Self-citation
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging
Pontecorvo, M. J., Arora, A., Devine, M., Lu, M., Galante, N., Siderowf, A., Devadanam, C., Joshi, A. D., Heun, S. L., Teske, B. F., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3601-4 · Cited by 68
Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer’s Disease
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 69
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
Clinical Amyloid Imaging
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 64
The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging
Fantoni, E., Collij, L. E., Alves, I. L., Buckley, C. J., & Farrar, G. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235879 · Cited by 65
Self-citation
Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer’s Disease: A Blinded Validation Study
Youn, Y. C., Lee, B. S., Kim, G. J., Ryu, J. S., Lim, K., Lee, R., Suh, J., Park, Y. H., Pyun, J., Ryu, N., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200061 · Cited by 65
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 68
Fluorine-18: A radionuclide with diverse range of radiochemistry and synthesis strategies for target based PET diagnosis
Nerella, S. G., Joshi, R. K., Bharath, R. D., & Kumar, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111979 · Cited by 60
Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease
Li, T.-R., Wang, X.-N., Sheng, C., Li, Y.-X., Li, F. Z.-T., Sun, Y., & Han, Y. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111175 · Cited by 60
Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis
Heurling, K., Leuzy, A., Zimmer, E. R., Lubberink, M., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3208-1 · Cited by 59
Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia: A Systematic Review
Fink, H. A., Linskens, E. J., Silverman, P. C., McCarten, J. R., Hemmy, L. S., Ouellette, J. M., Greer, N. L., Wilt, T. J., & Butler, M. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3888 · Cited by 57
In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice
Ni, R., Villois, A., Deán‐Ben, X. L., Chen, Z., Vaas, M., Stavrakis, S., Shi, G., deMello, A. J., Ran, C., Razansky, D., et al. (2021) · Photoacoustics · doi:10.1016/j.pacs.2021.100285 · Cited by 55
Added value of 18 F‐florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study
Ceccaldi, M. P., Jonveaux, T., Verger, A., Krolak‐Salmon, P., Houzard, C., Godefroy, O., Shields, T., Perrotin, A., Gismondi, R., Bullich, S., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.009 · Cited by 56
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease
Ikonomović, M. D., Buckley, C. J., Abrahamson, E. E., Kofler, J., Mathis, C. A., Klunk, W. E., & Farrar, G. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02175-1 · Cited by 58
Self-citation
Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
Thal, D. R., Beach, T. G., Zanette, M., Lilja, J., Heurling, K., Chakrabarty, A., Ismail, A., Farrar, G., Buckley, C. J., & Smith, A. P. L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1897-9 · Cited by 58
Self-citation
Neuroimaging in aging and neurologic diseases
Risacher, S. L., & Saykin, A. J. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00012-1 · Cited by 56
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A. K., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 56
Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers
Bensaïdane, M. R., Beauregard, J., Poulin, S. P., Buteau, F.-A., Guimond, J. V., Bergeron, D., Verret, L., Fortin, M., Houde, M., Bouchard, R. W., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151180 · Cited by 50
Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease
Adamczuk, K., Schaeverbeke, J. M., Vanderstichele, H., Lilja, J., Nelissen, N., Laere, K. V., Dupont, P. J., Hilven, K., Poesen, K., & Vandenberghe, R. R. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0159-5 · Cited by 49
Self-citation
Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology
Beach, T. G., Thal, D. R., Zanette, M., Smith, A. P. L., & Buckley, C. J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150732 · Cited by 48
Self-citation
Patient and caregiver reactions to clinical amyloid imaging
Grill, J. D., Cox, C. G., Kremen, S. A., Mendez, M. F., Teng, E., Shapira, J. S., Ringman, J. M., & Apostolova, L. G. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.001 · Cited by 48
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 48
Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
Delmotte, K., Schaeverbeke, J. M., Poesen, K., & Vandenberghe, R. R. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00817-4 · Cited by 49
Self-citation
A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?
Beach, T. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0072-x · Cited by 50
Self-citation
Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update
Jan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00356 · Cited by 49
Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
Müller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanović, N., Knapskog, A., & Revheim, M. E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221365 · Cited by 48
State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer’s disease: Challenges and opportunities
Engels, N., Koops, E. A., Prokopiou, P. C., Egroo, M. V., Schneider, C., Riphagen, J. M., Singhal, T., & Jacobs, H. I. L. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104998 · Cited by 45
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Collij, L. E., Bischof, G. N., Altomare, D., Bader, I., Battle, M. R., García, D. V., Alves, I. L., Wolz, R., Gismondi, R., Stephens, A. W., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268119 · Cited by 48
Self-citation
Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods
Jovalekic, A., Roé-Vellvé, N., Koglin, N., Lagos‐Quintana, M., Nelson, A. S., Diemling, M., Lilja, J., Gómez-González, J. P., Doré, V., Bourgeat, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06279-0 · Cited by 47
Discovery of High-Affinity Amyloid Ligands Using a Ligand-Based Virtual Screening Pipeline
Chisholm, T. S., Mackey, M. D., & Hunter, C. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c03749 · Cited by 45
Amyloid Imaging: Poised for Integration into Medical Practice
Anand, K., & Sabbagh, M. N. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0474-y · Cited by 46
Self-citation
Neuropathological correlates of amyloid PET imaging in Down syndrome
Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomović, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 46
Amyloid PET imaging in clinical practice
Kolanko, M., Win, Z., Loreto, F., Patel, N., Carswell, C. J., Gontsarova, A., Perry, R. J., & Malhotra, P. (2020) · Practical Neurology · doi:10.1136/practneurol-2019-002468 · Cited by 47
In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer’s Brain Tissue
Ni, R., Röjdner, J., Voytenko, L. P., Dyrks, T., Thiele, A., Marutle, A., & Nordberg, A. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201344 · Cited by 42
Tenascin-C Is Associated with Cored Amyloid-β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly
Mi, Z., Halfter, W. M., Abrahamson, E. E., Klunk, W. E., Mathis, C. A., Mufson, E. J., & Ikonomović, M. D. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw062 · Cited by 43
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A., Devous, M. D., Navitsky, M. A., Kennedy, I. A., Joshi, A. D., Lu, M., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00653-x · Cited by 44
Self-citation
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Self-citation

Authors: Curtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., Walker, Z., Hunjan, A., Holmes, C., Escovar, Y. M., Vera, C. X., Agronin, M. E., Ross, J., Bozoki, A., Akinola, M., Shi, J., Vandenberghe, R., Ikonomovic, M. D., Sherwin, P. F., Grachev, I. D., Farrar, G., Smith, A. P. L., Buckley, C. J., McLain, R., & Salloway, S.
Affiliations: Compass Research (US)
Galiz Research, Miami Springs, Florida
Geriatric Solutions, Las Vegas, Nevada
Nova Southeastern University (US)
Premiere Research Institute (US)
Banner Sun Health Research Institute (US)
Mount Sinai Medical Center (US)
University of California San Diego (US)
University of Michigan (US)
University College London (GB)
North Essex Partnership University NHS Foundation Trust, Essex, England
University of Southampton (GB)
VERITAS Research, Miami Lakes, Florida
University of Miami (US)
Memory Enhancement Center of America (US)
Michigan State University (US)
Kennington Health Centre, Oxford, England
Barrow Neurological Institute (US)
Universitair Ziekenhuis Leuven (BE)
Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania
Medical Affairs, GE Healthcare–Life Sciences, Princeton, New Jersey
Novartis (United States) (US)
Amersham Hospital (GB)
PFP Statistical Consulting LLC, Livonia, Michigan
Brown University (US)
ORCID: Sabbagh, Marwan N.
Beach, Thomas G.
Duara, Ranjan
Fleisher, Adam S.
Frey, Kirk A.
Walker, Zuzana
Holmes, Clive
Agronin, Marc E.
Ross, Joel
Bozoki, Andrea
Shi, Jiong
Vandenberghe, Rik
Sherwin, Paul F.
Smith, Adrian P. L.
Buckley, Christopher J.
Salloway, Stephen
Venue: JAMA Neurology
Publisher: American Medical Association (AMA)
Published: 2015-03-01
Volume: 72
Issue: 3
Pages: 287
ISSN: 2168-6149 (ISSN-L)
DOI: 10.1001/jamaneurol.2014.4144
OpenAlex: W2164443763
Cited by: 332
References: 30
Citations by year: 2026: 17 · 2025: 41 · 2024: 26 · 2023: 20 · 2022: 29 · 2021: 34 · 2020: 36 · 2019: 29 · 2018: 20 · 2017: 24 · 2016: 33 · 2015: 22
FWCI: 26.77
Type: journal article
Language: en
Open access: green
lirias.kuleuven.be
Licence: other-oa
Locations: JAMA Neurology (publishedVersion)
PubMed (publishedVersion)
Lirias (submittedVersion, other-oa)
ePrints Soton (University of Southampton) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: Alzheimer's disease, sensitivity and specificity, dying patients, brain donation, dementia diagnosis
MeSH terms: Aged, Aged, 80 and over, Aniline Compounds, Female, Fluorine Radioisotopes, Humans, Male, Middle Aged, Single-Blind Method, Positron-Emission Tomography, Benzothiazoles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks